Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8521 safety and PK/PD in healthy and obese subjects
NCT02055547Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2013
- Primary completion
- Sep 2013
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of mk-8521 in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced at Least One Adverse Event (Part 1) at 8 weeks, Number of Participants Who Discontinued Treatment Due to an AE (Part 1) at 8 weeks and 7 more. Started May 2013; status: completed.
02
Drugs
mk-8521
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02055547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02055547.